|
Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients with Graft vs. Host Disease Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients with Graft vs. Host Disease conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients with Graft vs. Host Disease Clinical research trials and Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients with Graft vs. Host Disease healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients with Graft vs. Host Disease. Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients with Graft vs. Host Disease Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients with Graft vs. Host Disease clinical trial. Human subjects often receive the most effective healthcare possible for their Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients with Graft vs. Host Disease condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients with Graft vs. Host Disease  Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients with Graft vs. Host Disease
Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients with Graft vs. Host Disease
For Condition: Mycoses
Status: Completed
Sponsor(s): Schering-Plough ,
Synopsis: This trial is in high risk patients to determine the safety and efficacy of posaconazole (POZ) vs. fluconazole in the prophylaxis against development of invasive fungal infections (IFI).
Details: This study is designed to determine the safety, tolerance and efficacy of POZ used as prophylaxis of IFI in high-risk subjects with Grade II-IV acute graft vs. host disease (GVHD) or extensive chronic GVHD. The primary objective is to assess the efficacy of SCH56592 vs fluconazole in preventing proven or probable IFI within the time period from randomization to 16 weeks after the start of treatment with study drug.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 13 Years/65 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Hematopoietic progenitor cell transplant subjects with chronic or Grade II-IV acute GVHD being treated with high dose immunosuppressive therapy. - One of the following to the subject's prior immunosuppressive regimen: (a) at least 1mg per kg per day of methylprednisolone or equivalent, (b) Antithymocyte globulin (ATG) for the therapy of acute GVHD, (c) Tacrolimus, mycophenolate mofetil, or other steroid-sparing immunosuppressive regimen.
Total Enrollment: 600
Location and Contact Information:
Hospital Das Clinicas Da UFMG
Belo Horizonte, ,
Brazil
University Hospital of Wales
Cardiff, Wales,
United Kingdom
Department of Hematology and BMT
Katowice, ,
Poland
University of Maryland
Baltimore, Maryland,
United States
Additional Information:
Study ID Numbers: C/I98-316;
Study Start Date: February 1998
Record last reviewed: May 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00034645
Other Mycoses Studies:
1. Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients with Graft vs. Host Disease
2. A Multicenter, Open, Non-Comparative, Sequential Dose-Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Two Separate Doses of MK-0991 in Children with New Onset Fever and Neutropenia
3. An Open Label, Non-comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections
4. Emergency Use of Voriconazole in Patients with Life-Threatening Invasive Fungal Infections
5. Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections
Related Studies:
Other Mycoses Clinical Trials
Other Clinical Trials
Other Katowice Clinical Trials
Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients with Graft vs. Host Disease
|
|
|
|
|
|
|
|
